Direct Rx recalls DULOXETINE D/R
FDA Class II
FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.
- Hazard
- CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
- Products
-
- DULOXETINE D/R
- Company
- Direct Rx
- Where it was sold
-
U.S. Nationwide
Nationwide
- Units affected
- 263 Bottles
- About this recall
- DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.